| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vivo |
By lowering the phosphorylation of high-stress myocardial ERK, AKT, and GSK3β, KS370G (1 mg/kg; oral; once daily for 8 weeks) enhances left ventricular function and prevents cardiac hypertrophy [1]. By decreasing neuronal and oxidative stress, oral medication (once daily for 13 days) mitigates unilateral ureteral blockage-induced kidney fibrosis in mice [2].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Pressure overload ICR mouse model [1]
Doses: 1 mg/kg Route of Administration: po (oral gavage), one time/day for 8 weeks. Experimental Results: Inhibited cardiac hypertrophy caused by pressure overload and improved cardiac function. Decreases plasma levels of atrial natriuretic peptide and lactate dehydrogenase. Dramatically diminished pressure overload-induced increases in α-SMA and ERK, AKT, and GSK3β phosphorylation. Collagen accumulation in the heart is diminished. Animal/Disease Models: Male ICR mouse, unilateral ureteral obstruction (UUO) model [2] Doses: 10 mg/kg Route of Administration: Orally, one time/day for 13 days Experimental Results: Dramatically attenuated collagen deposition in the obstructed kidney, and inhibited UUO-induced expression of renal fibrosis markers, including fibronectin, type I collagen, vimentin, and α-smooth muscle actin (α-SMA). Dramatically diminished renal expression of inflammatory chemokines/adhesion molecules and monocyte markers (MCP-1, VCAM-1, ICAM-1 and CD11b). diminished renal malondialdehyde l |
| References |
[1]. Chuang ST, et al. KS370G, a caffeamide derivative, attenuates unilateral ureteral obstruction-induced renal fibrosis by the reduction of inflammation and oxidative stress in mice. Eur J Pharmacol. 2015 Mar 5;750:1-7.
[2]. Weng YC, et al. KS370G, a synthetic caffeamide derivative, improves left ventricular hypertrophy and function in pressure-overload mice heart. Eur J Pharmacol. 2012 Jun 5;684(1-3):108-15. [3]. Chuang ST, et al. KS370G, a caffeamide derivative, attenuates unilateral ureteral obstruction-induced renal fibrosis by the reduction of inflammation and oxidative stress in mice. Eur J Pharmacol. 2015 Mar 5;750:1-7. |
| Additional Infomation |
Caffeic Acid Phenethyl Amide has been reported in Annona cherimola with data available.
See also: Ipomoea aquatica leaf (part of). |
| Molecular Formula |
C17H17NO3
|
|---|---|
| Molecular Weight |
283.32
|
| Exact Mass |
283.121
|
| Elemental Analysis |
C, 72.07; H, 6.05; N, 4.94; O, 16.94
|
| CAS # |
105955-01-9
|
| PubChem CID |
11391937
|
| Appearance |
Solid powder
|
| LogP |
3.31
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
350
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(/C=C/C1C=CC(=C(C=1)O)O)NCCC1C=CC=CC=1
|
| InChi Key |
QOWABIXYAFJMQE-VQHVLOKHSA-N
|
| InChi Code |
InChI=1S/C17H17NO3/c19-15-8-6-14(12-16(15)20)7-9-17(21)18-11-10-13-4-2-1-3-5-13/h1-9,12,19-20H,10-11H2,(H,18,21)/b9-7+
|
| Chemical Name |
(E)-3-(3,4-dihydroxyphenyl)-N-(2-phenylethyl)prop-2-enamide
|
| Synonyms |
KS 370 G; KS-370-G; KS370G
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~352.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5296 mL | 17.6479 mL | 35.2958 mL | |
| 5 mM | 0.7059 mL | 3.5296 mL | 7.0592 mL | |
| 10 mM | 0.3530 mL | 1.7648 mL | 3.5296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
